GT200800227A - Antagonistas del receptor de vanilloides del subtipo (vr1) y usos de los mismos - Google Patents

Antagonistas del receptor de vanilloides del subtipo (vr1) y usos de los mismos

Info

Publication number
GT200800227A
GT200800227A GT200800227A GT200800227A GT200800227A GT 200800227 A GT200800227 A GT 200800227A GT 200800227 A GT200800227 A GT 200800227A GT 200800227 A GT200800227 A GT 200800227A GT 200800227 A GT200800227 A GT 200800227A
Authority
GT
Guatemala
Prior art keywords
receiver
subtipo
antigonists
vanilloid
same
Prior art date
Application number
GT200800227A
Other languages
English (en)
Inventor
Brian S Brown
John R Koenig
Arthur R Gomtsyan
Lee Chih-Hung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200800227A publication Critical patent/GT200800227A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Abstract

LA PRESENTE INVENCION SE RELACIONA CON COMPUESTOS ESPIROCROMANO QUE SON UTILES PARA EL TRATAMIENTO DE TRASTORNOS CAUSADOS POR O EXACERBADOS POR LA ACTIVIDAD DEL RECEPTOR DE VAINILLOIDES DEL TIPO 1 (VR1). LA PRESENTE INVENCION TAMBIEN INCLUYE COMPOSICIONES FARMACEUTICAS QUE CONTIENE COMPUESTOS Y METODOS PARA EL TRATAMIENTO DE VARIOS TIPOS DE DOLORES, HIPERACTIVIDAD VESICAL E INCONTINENCIA URINARIA USANDO LOS MENCIONADOS COMPUESTOS. T2008
GT200800227A 2006-04-18 2008-10-21 Antagonistas del receptor de vanilloides del subtipo (vr1) y usos de los mismos GT200800227A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79269906P 2006-04-18 2006-04-18

Publications (1)

Publication Number Publication Date
GT200800227A true GT200800227A (es) 2009-07-09

Family

ID=38610380

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200800227A GT200800227A (es) 2006-04-18 2008-10-21 Antagonistas del receptor de vanilloides del subtipo (vr1) y usos de los mismos

Country Status (20)

Country Link
US (2) US7622493B2 (es)
EP (1) EP2012778A4 (es)
JP (1) JP2009534399A (es)
KR (1) KR20080111144A (es)
CN (2) CN102796086A (es)
AU (1) AU2007238071B2 (es)
BR (1) BRPI0710507A2 (es)
CA (1) CA2647256A1 (es)
CR (1) CR10362A (es)
EC (1) ECSP088888A (es)
GT (1) GT200800227A (es)
MX (1) MX2008013428A (es)
MY (1) MY144307A (es)
NO (1) NO20084729L (es)
NZ (1) NZ571706A (es)
RU (1) RU2450006C2 (es)
TW (1) TWI357904B (es)
UA (1) UA94940C2 (es)
WO (1) WO2007121299A2 (es)
ZA (1) ZA200808691B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057543A1 (es) * 2005-10-07 2007-12-05 Glenmark Pharmaceuticals Sa Derivados de benzofusionado sustituido utilizables como ligandos receptores de vainiloide
EP2012778A4 (en) * 2006-04-18 2011-08-10 Abbott Lab VANILLOID RECEPTOR (VR1) SUBType 1 ANTAGONISTS AND USES THEREOF
WO2008110863A1 (en) * 2007-03-15 2008-09-18 Glenmark Pharmaceuticals S.A. Indazole derivatives and their use as vanilloid receptor ligands
WO2009081219A1 (en) * 2007-12-20 2009-07-02 Glenmark Pharmaceuticals, S.A. Quinazoline derivatives as vanilloid receptor modulators
WO2009095726A1 (en) * 2008-01-29 2009-08-06 Glenmark Pharmaceuticals, S.A. Acrylamide derivatives as vanilloid receptor 1 modulators
US8609692B2 (en) 2008-10-17 2013-12-17 Abbvie Inc. TRPV1 antagonists
WO2010045401A1 (en) 2008-10-17 2010-04-22 Abbott Laboratories Trpv1 antagonists
JP2013526542A (ja) 2010-05-12 2013-06-24 アッヴィ・インコーポレイテッド キナーゼのインダゾール阻害薬
CN103635458B (zh) 2011-03-25 2016-10-19 艾伯维公司 Trpv1拮抗剂
US8859584B2 (en) 2011-12-19 2014-10-14 Abbvie, Inc. TRPV1 antagonists
US8969325B2 (en) 2011-12-19 2015-03-03 Abbvie Inc. TRPV1 antagonists
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US8796328B2 (en) 2012-06-20 2014-08-05 Abbvie Inc. TRPV1 antagonists
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6997358B2 (ja) 2018-09-30 2022-01-17 メッドシャイン ディスカバリー インコーポレイテッド キノリノピロリジン－２－オン系誘導化合物及びその使用
RU2755206C1 (ru) 2020-05-20 2021-09-14 Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) Средство пролонгированного анальгетического действия и лекарственный препарат на его основе

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2745305A1 (de) * 1977-10-07 1979-04-19 Bayer Ag Insektizide und akarizide mittel
US5374643A (en) 1992-09-11 1994-12-20 E. R. Squibb & Sons, Inc. Aryl urea (thiourea) and cyanoguanidine derivatives
RU2156250C2 (ru) * 1995-04-24 2000-09-20 Новартис Аг Производные хромона, способ их получения и фармацевтическая композиция
WO2002020509A2 (de) * 2000-09-06 2002-03-14 Bayer Aktiengesellschaft Arzneimittel gegen virale erkrankungen
DE10120619A1 (de) * 2001-04-26 2002-10-31 Merck Patent Gmbh 2-(5-(4-Fluorphenyl)-3-pyridylmethylaminomethyl-chroman
GB0110901D0 (en) * 2001-05-02 2001-06-27 Smithkline Beecham Plc Novel Compounds
US6821971B2 (en) * 2001-09-20 2004-11-23 The Procter & Gamble Company Fused pyrazolone compounds which inhibit the release of inflammatory cytokines
ATE420644T1 (de) * 2002-02-20 2009-01-15 Abbott Lab Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
US6984647B2 (en) 2002-05-17 2006-01-10 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid VR1 receptor
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7514562B2 (en) 2003-03-07 2009-04-07 Glaxo Group Limited Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain
SI2017265T1 (sl) * 2003-06-12 2011-09-30 Abbott Lab Kondenzirane spojine za inhibicijo vaniloidnega receptorja podvrste (VR1) receptorja
EP1589015A1 (en) * 2004-02-03 2005-10-26 Université de Liège Benzopyran derivatives, method of production and use thereof
EP1844038A2 (en) * 2004-11-24 2007-10-17 Abbott Laboratories Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof
AU2005316739A1 (en) * 2004-12-13 2006-06-22 Galileo Pharmaceuticals, Inc. Spiro derivatives as lipoxygenase inhibitors
US7615570B2 (en) * 2004-12-13 2009-11-10 Abbott Laboratories Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
KR20080014024A (ko) * 2005-05-11 2008-02-13 아보트 러보러터리즈 바닐로이드 수용체 아형 １(ｖｒ１)의 길항제 및 이의 용도
CN101321766A (zh) * 2005-10-07 2008-12-10 格兰马克药品股份有限公司 取代的苯并稠合的衍生物及其作为香草素受体配体的用途
AR057543A1 (es) * 2005-10-07 2007-12-05 Glenmark Pharmaceuticals Sa Derivados de benzofusionado sustituido utilizables como ligandos receptores de vainiloide
JP2009513659A (ja) 2005-10-28 2009-04-02 アボット・ラボラトリーズ Ｔｒｐｖ１受容体を阻害するインダゾール誘導体
EP2012778A4 (en) * 2006-04-18 2011-08-10 Abbott Lab VANILLOID RECEPTOR (VR1) SUBType 1 ANTAGONISTS AND USES THEREOF
PE20081692A1 (es) * 2007-01-24 2008-12-18 Mochida Pharm Co Ltd Nuevo derivado de heterocicliden acetamida
WO2008110863A1 (en) * 2007-03-15 2008-09-18 Glenmark Pharmaceuticals S.A. Indazole derivatives and their use as vanilloid receptor ligands

Also Published As

Publication number Publication date
CA2647256A1 (en) 2007-10-25
WO2007121299A3 (en) 2008-11-13
ZA200808691B (en) 2010-03-31
US8598220B2 (en) 2013-12-03
TWI357904B (en) 2012-02-11
BRPI0710507A2 (pt) 2011-08-16
RU2450006C2 (ru) 2012-05-10
WO2007121299A2 (en) 2007-10-25
AU2007238071B2 (en) 2012-06-07
UA94940C2 (ru) 2011-06-25
ECSP088888A (es) 2008-12-30
NO20084729L (no) 2008-11-10
RU2008145506A (ru) 2010-05-27
EP2012778A4 (en) 2011-08-10
NZ571706A (en) 2012-06-29
US7622493B2 (en) 2009-11-24
EP2012778A2 (en) 2009-01-14
CN101426498A (zh) 2009-05-06
JP2009534399A (ja) 2009-09-24
KR20080111144A (ko) 2008-12-22
US20070249614A1 (en) 2007-10-25
MY144307A (en) 2011-08-29
AU2007238071A1 (en) 2007-10-25
TW200808808A (en) 2008-02-16
CN102796086A (zh) 2012-11-28
US20090233953A1 (en) 2009-09-17
CR10362A (es) 2008-12-11
MX2008013428A (es) 2008-11-04

Similar Documents

Publication Publication Date Title
GT200800227A (es) Antagonistas del receptor de vanilloides del subtipo (vr1) y usos de los mismos
CU23464B7 (es) (1,8)naftidirin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
UY28157A1 (es) Miméticos de glucocorticoides métodos para su elaboración composiciones farmacéuticas y sus usos
HN2008001464A (es) Formulaciones para administrcion parenteral de compuestos y sus usos
ECSP034428A (es) Ciclopentanoindoles, composiciones conteniendo tales compuestos y su uso
CR11017A (es) Anticuerpos anti-robo4 y sus usos
PA8596901A1 (es) Inhibidores de p38 y metodos de uso de ellos
GT200800198A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide del tipo 1.
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
ECSP088298A (es) Modulacion de la expresion del receptor glucocorticoide
EA201000149A1 (ru) Производные 1-фенил-2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстераз
EA201001371A1 (ru) Конденсированные пиримидиноновые соединения как модуляторы trpv3
NO20061845L (no) Fenyl-piperazinderivater som modulatorer for muskarine reseptorer
DOP2012000314A (es) Compuestos, composiciones de tiocetato y metodos de uso
CR11007A (es) Formulaciones estables de de acido s-(+)- abscisico liquidas y de granulo soluble
ECSP077421A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
ECSP088306A (es) Agentes para prevenir y tratar los trastornos que involucran la modulación de los receptores ryr
CR8879A (es) Bifeniltiazolcarboxamidas
PA8663501A1 (es) Derivados de indol, benzotiofeno, benzofurano e indeno cicloalquilcondensados
ECSP066716A (es) Antagonistas del receptor hidroisoindolina taquiquinina
CR10062A (es) Composiciones y metodos de tratamiento para trastornos del sistema nervioso central
CL2004000732A1 (es) Compuestos derivados de oximas sustituidas y sus sales farmaceuticamente aceptables; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los contiene; y uso de los compuestos para el tratamiento del cancer.
RS20080246A (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors